Background: Our previous study showed that SLC22A18 downregulation and promoter methylation were associated with the development and progression of glioma and the elevated expression of SLC22A18 was found to increase the sensitivity of glioma U251 cells to the anticancer drug 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). In this study, we investigated the predictive value of SLC22A18 promoter methylation and protein expression in glioblastoma multiforme (GBM) patients receiving temozolomide (TMZ) therapy. Patients and methods: SLC22A18 promoter methylation and protein expression were examined by methylationspecific polymerase chain reaction (MSP) and Western blotting respectively, then we compared SLC22A18 promoter methylation and protein expression in tumor cell explants in regard to prediction of TMZ response and survival time of 86 GBM patients.
Background
Glioblastoma multiforme (GBM) is the most common and lethal glial tumor of the adult brain, accounting for about fifty percent of all gliomas. It is characterized by an aggressive growth pattern, a marked degree of the invasiveness and very poor prognosis. The standard treatment for malignant glioma patients was resection followed by radiotherapy in the past many years. Lately a great lot of researches revealed a statistically significant survival benefit for GBM patients treated with radiotherapy plus temozolomide (TMZ) [1, 2] . Consequently, radiotherapy plus concurrent TMZ therapy currently represents the standard of care for newly diagnosed GBM patients [3] .
Solute carrier family 22 (organic cation transporter) member 18 (SLC22A18), also known as IMPT1/BWR1A/ TSSC5, is located within the human 11p15.5 cluster [4, 5] . Blast homology analysis suggests that SLC22A18 is a member of the family of polyspecific transporters and multidrug resistance genes [5] . More recently, SLC22A18 has been shown to be a tumor suppressor candidate and a substrate for RING105 [6] . Structural mutations in SLC22A18 are rare, with isolated reports of point mutations in a breast cancer cell line [7] , a rhabdomyosarcoma cell line [5] , and Wilms' tumors and lung tumors [8] . Exonic deletions in Wilms' tumors and loss of heterozygosity in hepatoblastomas have also been reported [9] , indicating that SLC22A18 may play a role in tumorigenesis. We have previously found that SLC22A18 downregulation and promoter methylation were associated with the development and progression of glioma and SLC22A18 represented a candidate biomarker for long-term survival in this disease, suggesting that SLC22A18 is an important tumor suppressor in glioma [10, 11] . We have also found that the elevated expression of SLC22A18 was found to increase the sensitivity of glioma U251 cells to the anticancer drug 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) [12] .
In this study, for the first time we used primary tumor cell explants obtained from GBM surgical specimens instead of tissue samples to investigate SLC22A18 methylation promoter and protein expression of tumor cell. Our data presented show that expression of SLC22A18 protein has a very strong predictive value for TMZ response and survival time in GBM patients.
Materials and methods

Study patients
We collected 86 cases of surgically resected GBMs in the period ranging from [2007] [2008] [2009] [2010] Ethics Committees (Ethic approval ZNHWHU0389,NTPH-SHJTUSM046) was obtained before the clinical materials were used for research purposes. All experiments on humans in the present study were performed in compliance with the Helsinki Declaration. Gadolinium-enhanced MRI performed within 1 week after surgery was used to categorize the surgical results according to the removed tumor proportion, i.e., biopsy, ≤ 50%; partial removal, 50-95%; subtotal removal, 96-99%; total removal, >99%. There were 46 men and 40 women with a mean age of 62.5 years (range from 14 to 78 years). None of the patients had received chemical therapy or radiotherapy prior to surgery. 50 patients received concurrent radiotherapy and chemotherapy (60 Gy and daily TMZ at 75 mg/m 2 ; 7 days per week over a 42-day period) after surgery. 30 patients received the adjuvant TMZ after concurrent radio-temozolomide therapy. 36 patients did not receive chemotherapy, out of which 18 had only radiotherapy and 18 did not have further therapy. Characteristics of the patients according to SLC22A18 promoter methylation and protein expression status were shown in Table 1 .
Primary tumor cell cultures
After removing visible blood vessel and necrotic tissues, surgery specimens were processed for primary cell cultures as described previously [13] [14] [15] , and analyzed between passages 2 and 6. During resection patches from non-necrotic parts of the tumors were gained, disaggregatd mechanically and transferred into culture flasks, containing growth medium (RPMI-1640, 20% fetal bovine serum, 1% penicillin/streptomycine, 1% glutamine; Gibco Life Technologies, Paisley, Scotland, UK). Three to five culture flasks were set up from each surgery specimen. Cells were then cultured in RPMI-1640 supplemented with 10% fetal bovine serum and 1% glutamine and without antibiotics. The presence of predominantly malignant cells in primary cell cultures was proved by comparative genomic hybridization and/or fluorescent in situ hybridization analyses [13] . All cell cultures were periodically checked for Mycoplasma contamination using a Mycoplasma Stain Kit (Sigma-Aldrich, St. Louis, Missouri, USA) [16] .
DNA extraction and methylation-specific polymerase chain reaction
As we've previously described [10, 17] , genomic DNA was extracted from tumor cell cultures or frozen surgery tissues by the digestion with proteinase K (Fisher Scientific, Fairlawn, NJ, USA) using a genomic DNA purification kit (PureGene kit, Gentra Systems, Inc., Minneapolis, MN, USA), and 1 μg genomic DNA was treated with a CpG WIZ DNA Modification Kit (EMD Millipore Corporation, Billerica, MA, USA) to convert unmethylated cytosines to uracil, leaving methylated cytosines unchanged. The modified DNA was diluted in TE buffer (10 mM Tris-Cl, pH 7.5. 1 mM EDTA). SLC22A18 and MGMT promoter methylation analysis was performed by PCR, using bisulfite-treated DNA as template, with specific primers for the methylated (unmodified by bisulfite treatment) and unmethylated (bisulfite modified) gene sequences using the methylationspecific polymerase chain reaction (MSP) method [10, 17] . Expression levels were quantified by Quantity One Quantitation software (BioRad) and calculated relative to the controls. The results were confirmed by repeating the bisulfite treatment and MSP assays for all samples.
Western blot analysis
As we've previously described [18] [19] [20] , tumor cell cultures were washed in ice-cold PBS and lysed in buffer using standard methods. tumor tissues were homogenized in a RIPA lysis buffer. Lysates were cleared by centrifugation (14, 000 rpm) at 4°C for 30 minutes. Protein samples (approximately 40 μg) were separated by SDS-PAGE (15% gel), transferred to PVDF membrane and nonspecific binding sites blocked by incubation in 5% non-fat milk for 60 minutes. Membranes were incubated overnight at 4°C with polyclonal anti-SLC22A18 antibody (1:1,000 dilution; Santa Cruz, CA). The membrane was then washed three times with TBST for 10 minutes and probed with HRP-conjugated secondary antibody (at 1:2,000 dilution; Dako, Glostrap, Denmark) for 30 minutes at room temperature. Visualization and quantification were done using the ChemiDoc System (BioRad). Data gained by the densitometric analysis of Western blotting for SLC22A18 were expressed relative (arbitrary units) to the SLC22A18 expressing human neurons (ScienCell Research Laboratories, San Diego, CA, USA) that is included as a positive control in each blot and set arbitrarily as 1.
Each assay was performed in triplicate.
Statistical analyses
Statistical analyses and graphs were performed using the Statistical Package for the Social Sciences (version 16.0, for Windows) (SPSS, Chicago, IL, USA). Quantitative values were expressed as mean ± SD. Statistical differences between groups were examined using the Fisher's exact test. P-values less than 0.05 were considered statistically significant.
Results
SLC22A18 promoter methylation and protein expression
Primary tumor cell culture was successful in vitro in all surgery specimens, allowing SLC22A18 promoter methylation and protein expression analyses. In 61 of 86 (71%) GBM cases methylated SLC22A18 gene promoter sequences were detected. Out of the 61 samples with methylated sequences, 24 samples contained a mixed profile with varying proportions of unmethylated and methylated sequences, whereas the remaining 37 cases (61%) lacked any unmethylated DNA ( Figure 1A -B). SLC22A18 promoter was completely unmethylated in 25 of 86 (29%) GBM cases. To investigate the potential influence of tumor cell culture, SLC22A18 promoter methylation was determined in both surgical tissues and the respective tumor cell cultures in 86 cases. SLC22A18 methylation status agreed well in all patients (see Additional file 1: Table S1 ), and semi-quantification of MSP products for methylated DNA sequences showed a significant correlation (linear regression analysis, P < 0.001).
In all cell cultures SLC22A18 protein expressions were successfully analyzed by Western blotting ( Figure 1C) . 36 of the 86 cases (42%) were scored positive for SLC22A18 protein expression based on a visible band and corresponding to a relative expression level > 0.1. Neither SLC22A18 promoter methylation nor protein expression was significantly correlated with any of the clinical features listed in Table 1 . The mean SLC22A18 expression levels were significantly lower in tumor cell cultures harboring methylated SLC22A18 promoter sequences when compared with only unmethylated subgroup (P < 0.001) ( Figure 1D ). Therefore, SLC22A18 protein expression was significantly associated with promoter methylation status when analyzed by 2-sided χ 2 test (P < 0.001). SLC22A18 protein expression levels in the subgroups were strongly overlapping according to promoter methylation despite this association ( Figure 1D ). In Figure 2 data of 4 representative samples that did not follow the correlation between SLC22A18 protein expression and promoter methylation status were shown. These findings included cases with exclusively unmethylated promoter sequences but lack of SLC22A18 protein expression as well as high expression of SLC22A18 protein, despite completely methylated promoter.
Relationship between SLC22A18 status and overall survival of GBM patients with/without TMZ therapy 58 (67%) of 86 cases had died (34 of 35 cases without TMZ treatment and 24 of 51 cases with TMZ treatment) at a median follow-up time of 27.1 months (95% CI 
25.8-30.2)
. By univariate analyses the overall survival of GBM patients was compared to SLC22A18 protein expression or promoter methylation status (Table 2 ). In the univariate analysis lack of SLC22A18 protein expression (hazard ratio [HR] of death 2.14, 95% CI 1.24-3.72; P = 0.01), but not promoter methylation status (HR of death 0.64, 95% CI 0.32-1.15; P = 0.13), was significantly connected with shorter overall survival in addition to well-known prognostic factors such as age, performance status, extent of surgery, MGMT promoter methylation and TMZ therapy. Besides age, performance status, extent of surgery, MGMT promoter methylation and TMZ therapy, only lack of SLC22A18 protein expression, but not SLC22A18 promoter methylation status, remained as an independent prognostic factor (HR of death 2.11, 95% CI 1.09-3.77; P = 0.02) in multivariate Cox regression analysis (Table 3 ). An interaction term, the product of SLC22A18 parameter and TMZ therapy, was incorporated into the multivariate Cox regression models to evaluate a possible interaction between the SLC22A18 parameters and TMZ treatment. These findings showed a statistically significant association between SLC22A18 protein expression and TMZ treatment (P = 0.004), whereas in the case of SLC22A18 promoter methylation this interaction was not significant. Because the interaction term of SLC22A18 protein expression and TMZ therapy was significant, we studied the relationship between SLC22A18 protein expression and overall survival time in TMZ therapy and no TMZ therapy subgroups (Table 4, Figure 3A and B). In patients with TMZ therapy, SLC22A18 protein expression was significantly associated with longer overall survival time (HR of death 5.65, 95% CI 1.79-17.45; P = 0.002). Conversely, no differences in overall survival time according to SLC22A18 protein expression (HR of death 1.12, 95% CI 0.56-2.28; P = 0.62) were shown in patients without TMZ therapy. A similar study using the subgroups according to promoter methylation status showed no significant differences with overall survival time in the TMZ therapy subgroup (Figure 3C and D) .
Discussion
We have previously found that SLC22A18 protein expression was significantly decreased in human gliomas compared to the adjacent normal brain tissues. SLC22A18 protein expression was significantly lower in gliomas which recurred within six months after surgery than gliomas which did not recur within six months. Multivariate Cox regression analysis indicated that SLC22A18 expression level was an independent survival prognostic factor for patients with glioma. SLC22A18 promoter methylation was detected in 50% of the gliomas, but not in the adjacent normal tissues of any patient. SLC22A18 expression was significantly decreased in gliomas with SLC22A18 promoter methylation, compared to gliomas without methylation. The SLC22A18 promoter was methylated in U251 cells and treatment with the demethylating agent 5-aza-2-deoxycytidine increased SLC22A18 expression and reduced cell proliferation. Stable overexpression of SLC22A18 inhibited growth and adherence, induced apoptosis in vitro and reduced in vivo tumor growth of U251 cells [10, 11, 21] . We have also found that elevated expression of SLC22A18 increased the sensitivity of U251 glioma cells to BCNU [12] . Recently we have found that by increasing the expression of SLC22A18 hydroxyapatite nanoparticles could inhibit the growth of human glioma cells in vitro and in vivo [18] .
In the present study, we have studied the relationship between SLC22A18 promoter methylation and protein expression and the association of these two parameters with TMZ treatment as well as overall survival time of GBM patients. We determined SLC22A18 protein expression by Western blot analysis in primary tumor cells derived from the surgical specimens instead of tissue sections or tumor extracts in order to focus completely on the malignant cell compartment. To avoid problems arising from the tissue fixation and paraffin embedding, we used cell culturesderived DNA for detection of SLC22A18 promoter methylation satus; and MSP was performed comparably from tumor cells and snap-frozen tissue in a subgroup of tumors, confirming the presence of methylated SLC22A18 promoter sequences in all cases. During short-term in vitro cultivation of tumor cells, the observations also exclude possible changes in the SLC22A18 promoter methylation status. Using this new method, we demonstrate that SLC22A18 protein expression is a strong important predictive marker for the response of TMZ therapy and the related survival benefit. our results showed SLC22A18 protein expression was associated with longer overall survival time. Especially in patients with TMZ therapy, SLC22A18 protein expression was significantly associated with longer overall survival time, and in patients without TMZ therapy no significant differences in overall survival time according to SLC22A18 protein expression were shown. The reasons for the discrepancy of SLC22A18 expression in different tumor patients and a patient subgroup are unclear so far. Thus, future studies with larger sample sizes should be done to confirm this trend. SLC22A18 protein expression was of superior predictive value in GBM patients in our study despite a strong association between SLC22A18 promoter methylation and protein expression. These findings show that reliable SLC22A18 protein detection approach has to be developed to identify GBM patients likely to benefit from TMZ treatment. Consistent with this idea [10] , the SLC22A18 parameters showed significant correlation in this study, confirming that SLC22A18 promoter methylation is a major factor regulating SLC22A18 protein expression. However, as obvious from the scatter grams ( Figure 1D ) and depicted by selected patients (Figure 2 ), there are some tumor cell samples not following this association. This shows that SLC22A18 protein is still expressed in a subgroup of tumors with SLC22A18 promoter methylation and vice versa. The reasons for the discrepancy between SLC22A18 expression and promoter methylation in a patient subgroup are unclear so far. Our results show that epigenetic silencing via promoter methylation is an important but obviously not always decisive factor regulating SLC22A18 expression in GBM cells. With respect to therapy response and overall survival, SLC22A18 protein expression proved to be of significantly higher predictive power when compared with promoter methylation status in our samples. Our attempts to analyze SLC22A18 expression by immunohistochemistry in selected patient samples used in this study were inconclusive, and immunostaining neither correlated with SLC22A18 expression nor promoter methylation detected by Western blot, even when using identical antibodies (data not shown). Our data based on tumor cell explants and Western blot analysis turn out the high quality of SLC22A18 expression as a predictive marker for TMZ response in patients with GBM.
Conclusions
Collectively, we analyzed the influence of SLC22A18 status on the response of TMZ treatment and survival time of GBM patients by using a completely novel approach. Evaluation of SLC22A18 protein levels in GBM cell cultures derived from surgical specimens was proved to be a strongly predictive indicator for TMZ therapy-mediated survival time benefit with superior information power as compared to the MSP analysis of SLC22A18 promoter methylation. Accordingly, reproducible and reliable SLC22A18 protein detection methods have to be developed and tested with respect to their predictive value for the response of TMZ treatment in prospective studies involving more GBM patients.
